National Institutes of Health: Multiple Sclerosis trials

The registry lists 59 Multiple Sclerosis studies with National Institutes of Health as lead sponsor. 8 are open to participants now and 11 have results posted.

Phase 1 16Phase 2 24Phase 3 5Phase 4 1No phase 20(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal LeukoencephalopathyRecruitingNCT05849467Phase 1
• Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVORecruitingNCT03816345Phase 1
• Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)RecruitingNCT03109288Phase 1/2
• Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis PlaquesRecruitingNCT02784210Phase 2
• Pathological Basis of MRI Signal Changes in Multiple SclerosisRecruitingNCT02659956
• Natural History Study of Progressive Multifocal Leukoencephalopathy (PML)RecruitingNCT01730131
• Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the Central Nervous SystemRecruitingNCT00794352
• Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS)RecruitingNCT00001248
• PET Imaging of Cyclooxygenase in Multiple SclerosisTerminatedNCT05062083Phase 2Results posted
• COVID-19 Booster Vaccine in Autoimmune Disease Non-RespondersTerminatedNCT05000216Phase 2Results posted
• Tolebrutinib, a Brain-penetrant Bruton's Tyrosine Kinase Inhibitor, for the Modulation of Chronically Inflamed White Matter Lesions in Multiple SclerosisActive, not recruitingNCT04742400Phase 2Results posted
• Anakinra for the Treatment of Chronically Inflamed White Matter Lesions in Multiple SclerosisCompletedNCT04025554Phase 1/2Results posted
• Idebenone for Primary Progressive Multiple SclerosisCompletedNCT01854359Phase 1/2Results posted
• Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)TerminatedNCT01212094Phase 1/2Results posted
• A Cooperative Clinical Study of Abatacept in Multiple SclerosisCompletedNCT01116427Phase 2Results posted
• Clinical Trial of Idebenone in Primary Progressive Multiple Sclerosis (IPPoMS)CompletedNCT00950248Phase 1/2Results posted
• A Comparison of an Implanted Neuroprosthesis With Sensory Training for Improving Airway Protection in Chronic DysphagiaCompletedNCT00376506Phase 2Results posted
• High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) StudyCompletedNCT00288626Phase 2Results posted
• Atorvastatin (Lipitor) Therapy in Patients With Clinically Isolated Syndrome (CIS) at Risk for Multiple SclerosisCompletedNCT00094172Phase 2Results posted
• Ocrelizumab Discontinuation in Relapsing Multiple SclerosisActive, not recruitingNCT05285891Phase 4
• In Vivo Characterization of Inflammation With Ferumoxytol, an Ultrasmall Superparamagnetic Iron Oxide Nanoparticle, on 7 Tesla Magnetic Resonance ImagingCompletedNCT02511028Phase 1
• Natural History of Multiple Sclerosis and Its MimickersCompletedNCT02504840
• Oral Guanabenz for Multiple SclerosisTerminatedNCT02423083Phase 1
• Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple SclerosisCompletedNCT02330965
• T and B Cell Responses in Autoimmune DiseasesTerminatedNCT01947036
• Natural History of Optic NeuritisTerminatedNCT01851434
• Relating Genetic and Environmental Risk Scores to Multiple Sclerosis SusceptibilityCompletedNCT01617395
• Manganese-Enhanced Magnetic Resonance Imaging in Healthy Volunteers and People With Multiple SclerosisCompletedNCT01326715Phase 1
• Investigating Mechanism of Action of DAC HYP in the Treatment of High-Inflammatory Multiple Sclerosis (MS)CompletedNCT01143441Phase 1
• Brain Peripheral Benzodiazepine Receptors in Patients With Multiple SclerosisCompletedNCT00432900Phase 1
• Magnetic Resonance Imaging to Detect Brain Damage in Patients With Multiple SclerosisCompletedNCT00393588
• Immunological Mechanisms of Hematopoietic Stem Cell Transplantation in Multiple SclerosisCompletedNCT00342134Phase 2
• Biomarkers in Multiple SclerosisCompletedNCT00325988
• Magnetic Resonance Imaging to Detect Brain Damage in Patients With Multiple SclerosisCompletedNCT00321568
• Effects of Spinal Cord Injury on Female Sexual ResponseStatus unknownNCT00142714Not applicable
• Magnetic Resonance Imaging to Detect Brain Damage in Patients With Multiple SclerosisCompletedNCT00099307
• Treating Multiple Sclerosis With Sirolimus, an Immune System SuppressorTerminatedNCT00095329Phase 1/2
• The Effect of Sildenafil Citrate (Viagra® (Registered Trademark)) on Brain Blood Flow in Multiple Sclerosis PatientsCompletedNCT00094068
• Safety of RG2077 in Patients With Multiple SclerosisCompletedNCT00076934Phase 1
• Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple SclerosisCompletedNCT00071838Phase 2
• Treatment of Multiple Sclerosis Using Over the Counter InosineCompletedNCT00067327Phase 2
• MR Perfusion Imaging and Hypercapnia (Increased Carbon Dioxide) to Study New Blood Vessel Formation in Multiple SclerosisCompletedNCT00064909
• Improving Memory in Patients With Multiple SclerosisWithdrawnNCT00062972Phase 3
• Antibiotic Treatment Trial Directed Against Chlamydia Pneumonia in Multiple SclerosisCompletedNCT00043264Phase 2
• Treatment of Multiple Sclerosis With Copaxone and AlbuterolCompletedNCT00039988Not applicable
• Rolipram to Treat Multiple SclerosisCompletedNCT00011375Phase 2
• Yoga: Effect on Attention in Aging & Multiple SclerosisCompletedNCT00010998Phase 2
• Natural Antioxidants in the Treatment of Multiple SclerosisCompletedNCT00010842Phase 1/2
• Diagnostic Study of Quantitative Imaging and Spectroscopy in Patients With Multiple SclerosisStatus unknownNCT00006060
• A Maintenance Extension of Phase I Pilot Study of Chimeric Anti-CD4 Antibody M-T412 in Patients With Multiple SclerosisCompletedNCT00004816Phase 1
• Phase III Randomized, Double-Blind, Placebo-Controlled Study of Copolymer 1 for Relapsing-Remitting Multiple SclerosisCompletedNCT00004814Phase 3
• Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Multiple SclerosisCompletedNCT00004744Phase 3
• Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous MethylprednisoloneStatus unknownNCT00004645Phase 3
• Zenapax to Treat Multiple SclerosisCompletedNCT00001934Phase 2
• Safety, Tolerability, and Effectiveness of CGP77116 in Patients With Multiple Sclerosis (MS)CompletedNCT00001781Phase 2
• A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerability and Effect/Efficacy of Subcutaneously Administered Insulin-Like Growth Factor-1 (rhIGF) (CEP-151) in Multiple Sclerosis (MS) PatientsCompletedNCT00001669Phase 2
• Assessment of Patients With Multiple Sclerosis (MS)CompletedNCT00001156
• Longitudinal Optic Neuritis Study (LONS)Status unknownNCT00000147Not applicable
• Optic Neuritis Treatment Trial (ONTT)Status unknownNCT00000146Phase 3